JPRN-jRCT2061210051暂停1 期
A Multicenter, Open-label, Clinical Pharmacology Trial to Determine the Pharmacokinetics, Tolerability, and Safety of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia - A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Matsumaru Takehisa0 个研究点目标入组 60 人开始时间: 2021年11月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •1) Japanese patients who are between 18 and 64 years of age, inclusive, at the time of informed consent
- •2) Patients with a diagnosis of schizophrenia as defined by the DSM-5 criteria
- •3) Patients who are able to remain at the trial site for the protocol-defined hospitalization period
- •4) Patients with a body mass index [BMI = body weight (kg) / height (m)2] of no less than 18.5 kg/m2 and less than 35.0 kg/m2 at screening
- •5) Patients who are able to provide written informed consent (if the patient is a minor or is hospitalized for medical protection, his or her legally acceptable representative must also give informed consent) prior to commencement of any trial procedure and are judged by the investigator or subinvestigator to be able to meet all protocol-defined requirements
排除标准
- •1) Patients with a diagnosis of a concurrent mental disorder besides schizophrenia (eg, schizoaffective disorder, major depressive disorder, bipolar I disorder, bipolar II disorder, general anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, dementia or mild neurocognitive disorder, and personality disorder) as defined by the DSM-5 criteria. However, this exclusion does not apply to caffeine- or tobacco-related disorders.
- •2) Patients who fail to meet the mandatory washout periods for the prohibited concomitant drugs and foods before commencement of IMP administration, or patients who are anticipated to take any of the drugs or foods during the trial period
- •3) Patients who have received electroconvulsive therapy (ECT) within 60 days prior to the administration of IMP
- •4) Patients with clinically significant nervous, hepatic, renal, metabolic, blood, immune, cardiovascular, respiratory, or digestive system disorders
- •However, such patients may be enrolled if the condition is mild or well controlled and is considered to not affect safety or PK evaluations.
- •5) Patients who have met the DSM-5 diagnostic criteria for substance-related or addictive disorder, including alcohol and benzodiazepines but excluding caffeine and tobacco, within 180 days prior to the administration of IMP
- •6) Patients with a positive drug test at screening (according to the results from the central laboratory). However, such patients may be enrolled if their condition is not diagnosed as a substance-related or addictive disorder, according to the DSM-5 diagnostic criteria.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effect of Levonorgestrel-Emergency Contraception Tablet on Ovulation Inhibition in groups with a BMI that ranges underweight to obeseOvulationMedDRA version: 20.0Level: PTClassification code 10036251Term: Post coital contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: LLTClassification code 10033313Term: Ovulation inhibitedSystem Organ Class: 100000004860EUCTR2019-001143-43-GBGedeon Richter Plc.520
招募中
4 期
A multicentre study of the dose concentration response of febuxostat in patients with chronic gout.ACTRN12616000959471St Vincent's Hospital120
进行中（未招募）
1 期
Study to assess the Amyloid beta draining effect of Thiethylperazine (TEP) in subjects with newly diagnosed early-to-mild dementia due to Alzheimer’s Disease in comparison to healthy volunteersewly diagnosed early-to-mild dementia due to Alzheimer's DiseaseMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-000870-20-DEImmungenetics AG70
已完成
1 期
A Phase I, Open label, Multi-Center Clinical Pharmacological Study of nemolizumab with a Single-dose in Japanese Atopic Dermatitis Patients with moderate to severe pruritusAtopic dermatitis with pruritus who are inadequately controlled by existing therapiesJPRN-jRCT2080225290Maruho Co., Ltd.25
进行中（未招募）
1 期
A Study of Baricitinib in Children With COVID-19 (COV-BARRIER-PEDS)EUCTR2021-001338-21-BEEli Lilly and Company24